Replies to post #110740 on Biotech Values

[DewDiligence]

Pfizer would do its shareholders a favor by shutting down its basic research group, saving maybe $5B out the current $9 Billion it spends annually. (It'll still need the clinical trial group.) It then could use that $5 Bil to purchase its needed research.

Why are you so sure PFE could get more value for the $5B by outsourcing basic research?

[masterlongevity]

Pfe's clinical trial unit stinks too. they may as well just be a marketing organization IMHO.